O	0	7	Medical	Medical	JJ	B-NP
O	8	15	therapy	therapy	NN	I-NP
O	16	19	for	for	IN	B-PP
O	20	32	intermittent	intermittent	JJ	B-NP
O	33	45	claudication	claudication	NN	I-NP
O	45	46	.	.	.	O

O	47	54	Medical	Medical	JJ	B-NP
O	55	62	therapy	therapy	NN	I-NP
O	63	65	to	to	TO	B-VP
O	66	73	improve	improve	VB	I-VP
O	74	82	symptoms	symptom	NNS	B-NP
O	82	83	,	,	,	O
O	84	93	stabilise	stabilise	VBP	B-VP
O	94	97	the	the	DT	B-NP
O	98	108	underlying	underlie	VBG	I-NP
B-Multi-tissue_structure	109	117	vascular	vascular	JJ	I-NP
O	118	125	disease	disease	NN	I-NP
O	126	129	and	and	CC	O
O	130	137	improve	improve	VB	B-VP
B-Organism_subdivision	138	143	lower	low	JJR	B-NP
I-Organism_subdivision	144	148	limb	limb	NN	I-NP
O	149	157	outcomes	outcome	NNS	I-NP
O	158	160	is	be	VBZ	B-VP
O	161	163	an	an	DT	B-NP
O	164	173	important	important	JJ	I-NP
O	174	177	and	and	CC	I-NP
O	178	187	effective	effective	JJ	I-NP
O	188	195	adjunct	adjunct	NN	I-NP
O	196	198	to	to	TO	B-PP
O	199	208	lifestyle	lifestyle	NN	B-NP
O	209	221	modification	modification	NN	I-NP
O	222	225	and	and	CC	O
O	226	234	surgical	surgical	JJ	B-NP
O	235	237	or	or	CC	I-NP
B-Immaterial_anatomical_entity	238	250	endovascular	endovascular	JJ	I-NP
O	251	264	interventions	intervention	NNS	I-NP
O	265	267	in	in	IN	B-PP
O	268	276	patients	patient	NNS	B-NP
O	277	281	with	with	IN	B-PP
O	282	284	IC	IC	NN	B-NP
O	284	285	.	.	.	O

O	286	296	Randomised	Randomise	VBN	B-NP
O	297	304	placebo	placebo	NN	I-NP
O	305	315	controlled	controlled	JJ	I-NP
O	316	322	trials	trial	NNS	I-NP
O	323	327	have	have	VBP	B-VP
O	328	333	shown	show	VBN	I-VP
O	334	338	that	that	IN	B-SBAR
O	339	342	the	the	DT	B-NP
O	343	360	phosphodiesterase	phosphodiesterase	NN	I-NP
O	361	364	III	III	CD	I-NP
O	365	374	inhibitor	inhibitor	NN	I-NP
O	375	385	cilostazol	cilostazol	NN	I-NP
O	386	391	100mg	100mg	CD	I-NP
O	392	395	bid	bid	NN	I-NP
O	396	404	improves	improve	VBZ	B-VP
O	405	409	pain	pain	NN	B-NP
O	409	410	-	-	HYPH	O
O	410	414	free	free	JJ	B-NP
O	415	418	and	and	CC	I-NP
O	419	426	maximum	maximum	JJ	I-NP
O	427	434	walking	walk	VBG	I-NP
O	435	443	distance	distance	NN	I-NP
O	443	444	,	,	,	O
O	445	447	as	as	RB	B-CONJP
O	448	452	well	well	RB	I-CONJP
O	453	455	as	as	IN	I-CONJP
O	456	463	quality	quality	NN	B-NP
O	464	466	of	of	IN	B-PP
O	467	471	life	life	NN	B-NP
O	471	472	,	,	,	O
O	473	475	in	in	IN	B-PP
O	476	477	a	a	DT	B-NP
O	478	483	range	range	NN	I-NP
O	484	486	of	of	IN	B-PP
O	487	495	patients	patient	NNS	B-NP
O	496	500	with	with	IN	B-PP
O	501	513	intermittent	intermittent	JJ	B-NP
O	514	526	claudication	claudication	NN	I-NP
O	527	529	in	in	IN	B-PP
O	530	534	whom	whom	WP	B-NP
O	535	540	there	there	EX	B-NP
O	541	543	is	be	VBZ	B-VP
O	544	546	no	no	DT	B-NP
O	547	555	evidence	evidence	NN	I-NP
O	556	558	of	of	IN	B-PP
B-Tissue	559	565	tissue	tissue	NN	B-NP
O	566	574	necrosis	necrosis	NN	I-NP
O	575	577	or	or	CC	O
O	578	582	rest	rest	NN	B-NP
O	583	587	pain	pain	NN	I-NP
O	587	588	.	.	.	O

O	589	593	This	This	DT	B-NP
O	594	600	review	review	NN	I-NP
O	601	611	summarises	summarise	VBZ	B-VP
O	612	615	the	the	DT	B-NP
O	616	624	evidence	evidence	NN	I-NP
O	625	629	from	from	IN	B-PP
O	630	631	8	8	CD	B-NP
O	632	639	pivotal	pivotal	JJ	I-NP
O	640	646	trials	trial	NNS	I-NP
O	647	649	of	of	IN	B-PP
O	650	660	cilostazol	cilostazol	NN	B-NP
O	661	670	involving	involve	VBG	B-VP
O	671	675	over	over	IN	B-PP
O	676	680	2000	2000	CD	B-NP
O	681	689	patients	patient	NNS	I-NP
O	690	694	with	with	IN	B-PP
O	695	707	intermittent	intermittent	JJ	B-NP
O	708	720	claudication	claudication	NN	I-NP
O	721	728	treated	treat	VBN	B-VP
O	729	732	for	for	IN	B-PP
O	733	735	up	up	RB	B-NP
O	736	738	to	to	TO	I-NP
O	739	740	6	6	CD	I-NP
O	741	747	months	month	NNS	I-NP
O	747	748	.	.	.	O

O	749	754	There	There	EX	B-NP
O	755	757	is	be	VBZ	B-VP
O	758	771	comparatively	comparatively	RB	B-NP
O	772	776	less	less	JJR	I-NP
O	777	785	evidence	evidence	NN	I-NP
O	786	788	to	to	TO	B-VP
O	789	796	support	support	VB	I-VP
O	797	800	the	the	DT	B-NP
O	801	804	use	use	NN	I-NP
O	805	807	of	of	IN	B-PP
O	808	813	other	other	JJ	B-NP
O	814	823	treatment	treatment	NN	I-NP
O	824	834	modalities	modality	NNS	I-NP
O	835	838	for	for	IN	B-PP
O	839	845	relief	relief	NN	B-NP
O	846	848	of	of	IN	B-PP
O	849	857	symptoms	symptom	NNS	B-NP
O	858	860	in	in	IN	B-PP
O	861	873	intermittent	intermittent	JJ	B-NP
O	874	886	claudication	claudication	NN	I-NP
O	886	887	,	,	,	O
O	888	891	but	but	CC	O
O	892	897	there	there	EX	B-NP
O	898	900	is	be	VBZ	B-VP
O	901	913	considerable	considerable	JJ	B-NP
O	914	922	interest	interest	NN	I-NP
O	923	925	in	in	IN	B-PP
O	926	937	therapeutic	therapeutic	JJ	B-NP
O	938	950	angiogenesis	angiogenesis	NN	I-NP
O	951	953	to	to	TO	B-VP
O	954	961	promote	promote	VB	I-VP
O	962	965	new	new	JJ	B-NP
B-Multi-tissue_structure	966	972	vessel	vessel	NN	I-NP
O	973	982	formation	formation	NN	I-NP
O	983	986	and	and	CC	O
O	987	994	enhance	enhance	VBP	B-VP
O	995	1012	collateralisation	collateralisation	NN	B-NP
O	1013	1015	of	of	IN	B-PP
O	1016	1019	the	the	DT	B-NP
B-Organism_subdivision	1020	1025	lower	low	JJR	I-NP
I-Organism_subdivision	1026	1030	limb	limb	NN	I-NP
O	1031	1036	using	use	VBG	B-VP
O	1037	1048	recombinant	recombinant	JJ	B-NP
O	1049	1055	growth	growth	NN	I-NP
O	1056	1062	factor	factor	NN	I-NP
O	1063	1071	proteins	protein	NNS	I-NP
O	1072	1074	or	or	CC	O
O	1075	1079	gene	gene	NN	B-NP
O	1080	1088	transfer	transfer	NN	I-NP
O	1089	1099	strategies	strategy	NNS	I-NP
O	1099	1100	.	.	.	O

O	1101	1104	The	The	DT	B-NP
O	1105	1114	rationale	rationale	NN	I-NP
O	1115	1118	for	for	IN	B-PP
O	1119	1130	therapeutic	therapeutic	JJ	B-NP
O	1131	1143	angiogenesis	angiogenesis	NN	I-NP
O	1144	1146	is	be	VBZ	B-VP
O	1147	1156	discussed	discuss	VBN	I-VP
O	1156	1157	,	,	,	O
O	1158	1166	together	together	RB	B-ADVP
O	1167	1171	with	with	IN	B-PP
O	1172	1175	the	the	DT	B-NP
O	1176	1180	most	most	RBS	I-NP
O	1181	1187	recent	recent	JJ	I-NP
O	1188	1195	results	result	NNS	I-NP
O	1196	1200	from	from	IN	B-PP
O	1201	1211	randomised	randomise	VBN	B-NP
O	1212	1218	trials	trial	NNS	I-NP
O	1219	1221	in	in	IN	B-PP
O	1222	1230	patients	patient	NNS	B-NP
O	1231	1235	with	with	IN	B-PP
B-Multi-tissue_structure	1236	1246	peripheral	peripheral	JJ	B-NP
I-Multi-tissue_structure	1247	1255	arterial	arterial	JJ	I-NP
O	1256	1263	disease	disease	NN	I-NP
O	1263	1264	.	.	.	O

